Vitamin D Research

back to research menu

Treatment

• Vitamin D status of patients admitted to a hospital rehabilitation unit: relationship to function and progress.Am J Phys Med Rehabil. 2007 Jun;86(6):435–45.
• Successful treatment of refractory warts with topical vitamin D(3) derivative (maxacalcitol, 1alpha, 25‑dihydroxy‑22‑oxacalcitriol) in 17 patients.J Dermatol. 2007 Apr;34 (4):264–6.
• Treatment of pigmented lesions of neurofibromatosis 1 with intense pulsed‑radio frequency in combination with topical application of vitamin D(3) ointment.J Dermatol. 2007 Apr;34 (4):227–30.
• A meta‑analysis of second cancers after a diagnosis of nonmelanoma skin cancer: Additional evidence that solar ultraviolet‑B irradiance reduces the risk of internal cancers.J Steroid Biochem Mol Biol. 2007 Mar;103(3–5):668–74. Epub 2007 Jan 8.
• Medical management of patients over 50 years admitted to orthopedic surgery for low‑energy fracture.Joint Bone Spine. 2007 Mar;74(2):160–5. Epub 2006 Jul 21.
• Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL‑628 (elocalcitol).J Steroid Biochem Mol Biol. 2007 Jan 19;
• Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC‑Trial).Rheumatol Int. 2007 Jan 11;
• Cancer survival is dependent on season of diagnosis and sunlight exposure.Int J Cancer. 2006 Oct 1;119(7):1530–6.
• A system for improving vitamin D nutrition in residential care.Med J Aust. 2006 Aug 21;185(4):195–8.
• Effect of vitamin D supplementation on vitamin D status and bone turnover markers in young adults.Eur J Clin Nutr. 2006 Jun;60(6):727–33. Epub 2006 Jan 4.
• Public health strategies to overcome barriers to optimal vitamin d status in populations with special needs.J Nutr. 2006 Apr;136(4):1135–9.
• Human Mammary Epithelial Cells Express CYP27B1 and Are Growth Inhibited by 25‑Hydroxyvitamin D‑3, the Major Circulating Form of Vitamin D‑3.J Nutr. 2006 Apr;136(4):887–92.
• Toll‑like receptor triggering of a vitamin D‑mediated human antimicrobial response.Science. 2006 Mar 24;311(5768):1770–3. Epub 2006 Feb 23.
• Vitamin d levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine.Epilepsia. 2006 Mar;47(3):510–5.
• Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis.Rheumatol Int. 2006 Mar;26(5):445–53. Epub 2005 Nov 10.
• Pharmacological treatment to augment hole board habituation in prenatal Vitamin D‑deficient rats.Behav Brain Res. 2006 Jan 6;166(1):177–83. Epub 2005 Sep 26.
• 1,25‑Dihydroxyvitamin D inhibits lipopolysaccharide‑induced immune activation in human endothelial cells.Clin Exp Immunol. 2006 Jan;143(1):58–64.
• Effect of vitamin D and calcium supplementation on bone turnover in institutionalized adults with Down's Syndrome.Eur J Clin Nutr. 2005 Dec 14;
• Effects of vitamin D analogs on the expression of plasminogen activator inhibitor‑1 in human vascular cells.Thromb Res. 2005 Dec 18;
• Colon cancer and solar ultraviolet B radiation and prevention and treatment of colon cancer in mice with vitamin D and its Gemini analogs.J Steroid Biochem Mol Biol. 2005 Oct;97(1–2):111–20. Epub 2005 Sep 8.
• Annual intramuscular injection of a megadose of cholecalciferol for treatment of vitamin D deficiency: efficacy and safety data.Med J Aust. 2005 Jul 4;183(1):10–2.
• Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up‑regulated in myeloid cells by 1,25‑dihydroxyvitamin D3.FASEB J. 2005 Jul;19(9):1067–77.
• Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.Clin Rheumatol. 2005 Jun;24(3):232–8. Epub 2005 Jan 13.
• Vitamin D and calcium supplementation prevents severe falls in elderly community‑dwelling women: a pragmatic population‑based 3‑year intervention study.Aging Clin Exp Res. 2005 Apr;17(2):125–32.
• Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care.BMJ 2005;330:1003 (30 April)
• Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25‑hydroxylase (CYP27A1) in human prostate epithelial cells.Clin Exp Metastasis. 2005;22(3):265–73.
• A pilot study of oral calcitriol (1,25‑dihydroxyvitamin D3) for relapsing‑remitting multiple sclerosis.JNNP 2005;76:1294–1296.
• Inhibition of proliferation and induction of apoptosis by 25‑hydroxyvitamin D3‑3beta‑(2)‑Bromoacetate, a nontoxic and vitamin D receptor‑alkylating analog of 25‑hydroxyvitamin D3 in prostate cancer cells.Clin Cancer Res. 2004 Dec 1;10(23):8018–27.
• Failure to normalize parathyroid hormone during treatment of vitamin D deficiency in Asian patients.Clin Endocrinol (Oxf). 2004 Nov;61(5):603–6.
• Vitamin D supplementation improves neuromuscular function in older people who fall.Age Ageing. 2004 Nov;33(6):589–95.
• Cutting edge: 1,25‑dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression.J Immunol. 2004 Sep 1;173(5):2909–12.
• Toxicity and antineoplastic effect of (24R)‑1,24‑dihydroxyvitamin D3 (PRI‑2191).Steroids. 2004 Sep;69(10):629–35.
• Vitamin D2 Is Much Less Effective than Vitamin D3 in HumansJournal of Clinical Endocrinology & Metabolism 2004 Aug Vol. 89, No. 11 5387–5391
• Vitamin D3 from sunlight may improve the prognosis of breast‑, colon‑ and prostate cancer (Norway).Cancer Causes Control. 2004 Mar;15(2):149–58.
• Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation.J Clin Endocrinol Metab. 2003 Nov;88(11):5175–9.
• Calcium and vitamin D.Endocrinol Metab Clin North Am. 2003 Mar;32(1):181–94, vii–viii. Review.
• Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.Recent Results Cancer Res. 2003;164:273–88.
• Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial.BMJ 2003;326:469 (1 March)
• 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.CMAJ. 2002 Nov 12;167(10 Suppl):S1–34. Review.
• Plasma vitamin D and 25OHD responses of young and old men to supplementation with vitamin D3.J Am Coll Nutr. 2002 Aug;21(4):357–62.
• The effect of conventional vitamin D(2) supplementation on serum 25(OH)D concentration is weak among peripubertal Finnish girls: a 3‑y prospective study.Eur J Clin Nutr. 2002 May;56(5):431–7.
• Role of Ca(2+) and vitamin D in the prevention and treatment of osteoporosis.Pharmacol Ther. 2002 Jan;93(1):37–49. Review.
• Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism.Treat Endocrinol. 2002;1(5):313–27. Review.
• Vitamin D analogues for secondary hyperparathyroidism.Nephrol Dial Transplant. 2002;17 Suppl 10:10–9. Review.
• Vitamin D analogs for the treatment of secondary hyperparathyroidism.Blood Purif. 2002;20(1):109–12. Review.
• Treatment of vitamin D deficiency due to Crohn's disease with tanning bed ultraviolet B radiation.Gastroenterology. 2001 Dec;121(6):1485–8.
• Vitamin D analogues for the management of secondary hyperparathyroidism.Am J Kidney Dis. 2001 Nov;38(5 Suppl 5):S34–40. Review.
• Wintertime vitamin D deficiency in male adolescents: effect on parathyroid function and response to vitamin D3 supplements.Osteoporos Int. 2001;12(10):875–9.
• Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post‑menopausal osteoporosis.Cochrane Database Syst Rev. 2001;(1):CD000227. Review.
• Relationship between muscle strength and vitamin D metabolites: are there therapeutic possibilities in the elderly?Z Rheumatol. 2000;59 Suppl 1:39–41.
• Plasma 25‑hydroxyvitamin D responses of younger and older men to three weeks of supplementation with 1800 IU/day of vitamin D.J Am Coll Nutr. 1999 Oct;18(5):470–4.
• Treatment of glucocorticoid‑induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium.Calcif Tissue Int. 1999 Oct;65(4):337–40.
• Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin  D analog (D‑hormone) therapy.Calcif Tissue Int. 1999 Oct;65(4):295–306. Review.
• Resolution of vitamin D insufficiency in osteopenic patients results in rapid recovery of bone mineral density.J Clin Endocrinol Metab. 1999 Aug;84(8):2729–30.
• Vitamin D analogs: perspectives for treatment.Miner Electrolyte Metab. 1999 Jul–Dec;25(4–6):337–41. Review.
• Subclinical vitamin D deficiency in neonates: definition and response to vitamin D supplements.Am J Clin Nutr. 1997 Mar;65(3):771–8.
• Vitamin D prophylaxis in children with a single dose of 150,000 IU of vitamin D.Eur J Clin Nutr. 1996 Dec;50(12):807–10.
• Therapy of osteoporosis: calcium, vitamin D, and exercise.Am J Med Sci. 1996 Dec;312(6):278–86. Review.
• Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low‑dose corticosteroids in patients with rheumatoid arthritis. A randomized, double‑blind, placebo‑controlled trial.Ann Intern Med. 1996 Dec 15;125(12):961–8.
• Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada.CMAJ. 1996 Oct 15;155(8):1113–33.
• Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis.CMAJ. 1996 Oct 1;155(7):955–61. Review.
• Characterization of a vitamin D3‑resistant MCF‑7 cell line.Endocrinology. 1996 Feb;137(2):400–9.
• Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25‑dihydroxyvitamin D3.Endocrinology. 1995 Jan;136(1):20–6.
• Vitamin D supplementation in institutionalized elderly. Effects of vitamin D3 (100,000 IU) orally administered every 3 months on serum levels of 25‑hydroxyvitamin D.Rev Rhum Mal Osteoartic. 1990 Nov;57(11):809–13.
• Skin as the site of vitamin D synthesis and target tissue for 1,25‑dihydroxyvitamin D3. Use of calcitriol (1,25‑dihydroxyvitamin D3) for treatment of psoriasis.Arch Dermatol. 1987 Dec;123(12):1677–1683a. Review.
• Hypoparathyroidism during pregnancy: treatment with calcitriol.J Clin Endocrinol Metab. 1981 Apr;52(4):810–3.
• A case of hypoparathyroidism in a child with beta‑thalassemia successfully treated with 1 alpha‑hydroxy‑vitamin D3.Helv Paediatr Acta. 1981;36(2):171–3.
• Case report: hypoparathyroidism and iron storage disease. Treatment with 25‑hydroxy‑vitamin D3.Am J Med Sci. 1978 Nov–Dec;276(3):363–8.
• 1alpha‑hydroxycholecalciferol in the treatment of hypoparathyroidism.Acta Med Scand. 1977 Jan;201(1–2):3–7.
• Vitamin D: the discovery of its metabolites and their therapeutic applications.Pediatrics. 1976 May;57(5):729–41. Review.
• Treatment of hypoparathyroidism with 1,25‑dihydroxycholecalciferol.Clin Endocrinol (Oxf). 1976;5 Suppl:167S–173S.
• The kidney as an endocrine organ involved in the function of vitamin D.Am J Med. 1975 Jan;58(1):39–47. Review.
• "Anticonvulsant action" of vitamin D in epileptic patients? A controlled pilot study.Br Med J. 1974 May 4;2(5913):258–9.

back to research menu